ArticleMaterials today. Bio2026
Redox-immune modulating gadolinium vanadate based nanozymes for osteoarthritis therapy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) remains a highly prevalent degenerative joint disorder driven by a self-reinforcing cycle of reactive oxygen species (ROS) accumulation, inflammatory amplification, and chondrocyte dysfunction within the joint microenvironment. Herein, we developed a rare-earth (RE) doped-engineered gadolinium vanadate-based bioactive nanosystem through rational lanthanide modulation and pterostilbene loading for synergistic regulation of OA progression. Through precisely controlled RE lattice doping and electronic-structure optimization, GVCP exhibits potent enzyme-mimetic ROS-scavenging activity, thereby alleviating oxidative stress and suppressing inflammation in the pathological joint microenvironment. Beyond this upstream microenvironmental regulation, GVCP directly preserves chondrocyte homeostasis by attenuating apoptosis, accompanied by modulation of the p53 signaling pathway and restoration of the Bax/BCL-2 balance. Meanwhile, GVCP promotes macrophage polarization toward the reparative M2 phenotype, thereby contributing to immune remodeling favorable for cartilage protection. In addition, DFT calculations further reveal Re-doped-induced electron-transfer characteristics and catalytic energetics underlying the enhanced redox activity of the nanosystem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.